Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuplazid's Black Box: Warning May Depend On Antipsychotic Classification

Executive Summary

Advisory committee questions whether an antipsychotic drug class boxed warning should go in the Nuplazid label if it is approved; some debate whether the product is part of that class.

You may also be interested in...



Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

Stephen Hahn Takes US FDA Helm Under Cloud Of Doubt About Vaping Stance

HELP Committee ranking member Patty Murray said because of Hahn's evasive responses to questions about curbing youth e-cigarette use during committee meeeting, she would oppose his confirmation. She also said she was not convinced Hahn would uphold FDA standards.

New US FDA Commissioner Stephen Hahn Heads to White Oak Under Vaping Cloud

Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057548

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel